Related Experiment Video
Updated: Jul 15, 2026

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
Published on: June 7, 2018
CDKN1A as a target of senescence in heart failure: insights from a multiomics study
Rutao Bian1,2, Li Zhang1,2, Dongyu Li1,2
1Department of Cardiology, Zhengzhou Hospital of Traditional Chinese Medicine, Zhengzhou, Henan, China.
Insights
This study reveals that CDKN1A is causally linked to heart failure (HF) by promoting cardiomyocyte senescence. Findings identify CDKN1A as a therapeutic target for developing novel HF drugs.
Area of Science:
- Cardiology
- Genetics
- Molecular Biology
Background:
- Cardiomyocyte senescence is a key factor in heart failure (HF) pathogenesis.
- The precise triggers and causes of HF development and progression remain unclear.
Purpose of the Study:
- To investigate the genetic links between cardiomyocyte senescence and HF.
- To identify cell senescence-related genes (SRGs) associated with HF using multi-omics data.
Main Methods:
- Utilized CellAge, SenMayo, and scRNA-seq data to identify SRGs and analyze cardiac cell expression.
- Employed Mendelian Randomization (MR), including two-sample MR (TSMR) and summary-data-based MR (SMR), to explore causal relationships with HF.
- Validated findings using Bayesian colocalization, cis-eQTL, cis-mQTL, cis-pQTL analyses, and assessed druggability of therapeutic targets.
Main Results:
- Identified 39 SRGs in cardiomyocytes, with CDKN1A showing a causal relationship with HF in both discovery and validation sets.
- Confirmed CDKN1A as a pathogenic gene for HF via SMR, linking its methylation to HF risk loci.
- Bayesian colocalization and genetic variation analyses supported the results; two potential therapeutic drugs were identified.
Conclusions:
- Multi-omics data revealed CDKN1A's role in regulating cardiomyocyte senescence.
- Identified CDKN1A as a potential therapeutic target for HF drug development.
Background:
Cardiomyocyte senescence plays a crucial role as a pathological mechanism in heart failure (HF). However, the exact triggering factors and underlying causes of HF onset and progression are still not fully understood.
Objectives:
By integrating multi-omics data, this study aimed to determine the genetic associations between cardiomyocyte and HF using cell senescence-related genes (SRGs).
Methods:
The study utilized the CellAge database and the SenMayo dataset, combined with high-resolution single-cell RNA sequencing (scRNA-seq) data, to identify SRG and examine differences in cardiac cell expression. To explore the causal relationship with HF using Mendelian Randomization (MR). Genetic variations influencing gene expression, DNA methylation, and protein expression (cis-eQTL, cis-mQTL, and cis-pQTL) were analyzed using the two-sample MR (TSMR) and summary-data-based MR (SMR). Additionally, Bayesian colocalization analysis, germline genetic variation, and bulk RNA data were employed to strengthen the reliability of the results. The application potential of therapeutic targets is ultimately assessed by evaluating their druggability.
Results:
The expression of 39 SRGs in cardiomyocytes was identified. In the discovery set revealed that CDKN1A (OR = 1.09, 95% confidence interval (CI) 1.02-1.15, FDR = 0.048) could be causally related to HF, and the results are also replicated in the validation set (OR = 1.20, 95% confidence interval (CI) 1.10-1.30, FDR <0.0001). Based on the SMR method, CDKN1A was confirmed as a candidate pathogenic gene for HF, and its methylation (cg03714916, cg08179530) was associated with HF risk loci. The result is validated by Bayesian colocalization analysis, genetic variations, and bulk RNA data. The druggability analysis identified two potential therapeutic drugs.
Conclusion:
Based on multi-omics data, this study uncovered the reciprocal regulation of cardiomyocyte senescence through CDKN1A, providing potential targets for HF drug development.
Related Concept Videos
Pathophysiology of Heart Failure
Coronary Artery Disease II: Pathophysiology
Heart Failure II: Pathophysiology
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy

